Institutional members access full text with Ovid®

Severe acute respiratory syndrome vs. the Middle East respiratory syndrome

Hui, David S.a; Memish, Ziad A.b; Zumla, Alimuddinc,d

Current Opinion in Pulmonary Medicine: May 2014 - Volume 20 - Issue 3 - p 233–241
doi: 10.1097/MCP.0000000000000046
INFECTIOUS DISEASES: Edited by Alimuddin Zumla

Purpose of review: This review compares the clinical features, laboratory aspects and treatment options of severe acute respiratory syndrome (SARS) and the Middle East respiratory syndrome (MERS).

Recent findings: Bats are the natural reservoirs of SARS-like coronaviruses (CoVs) and are likely the reservoir of MERS coronavirus (MERS-CoV). Although a small number of camels have been found to have positive nasal swabs by real-time polymerase chain reaction and to carry antibody against MERS-CoV, the transmission route and the intermediary animal source remain uncertain amongst the sporadic primary cases. Both SARS-CoV and MERS-CoV may cause severe respiratory failure and extrapulmonary features such as diarrhoea, whereas mild or asymptomatic cases also occur in both conditions. In comparison with SARS, patients with MERS are older with male predominance, more comorbid illness and relatively lower human-to-human transmission potential. Although the viral kinetics of MERS-CoV remain unknown, nosocomial infections of MERS occur early within the first week of illness of the index case, whereas those of SARS occurred mainly in the second week of illness when the patient's upper airway viral load peaks on day 10 of illness. In-vitro data suggest that interferon (IFN) with or without ribavirin and mycophenolic acid may inhibit MERS-CoV, whereas protease inhibitors and IFN have inhibitory activity against SARS-CoV.

Summary: Although there are some similarities in the clinical features, MERS progresses to respiratory failure much more rapidly than SARS. The higher case fatality rate of MERS is likely related to older age and comorbid illness. More studies are needed to understand MERS-CoV in order to guide public health infection control measures and treatment.

aDepartment of Medicine & Therapeutics, Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong

bMinistry of Health, Al-Faisal University, Riyadh, Kingdom of Saudi Arabia

cDivision of Infection and Immunity, Department of Infection, Centre for Clinical Microbiology, University College London

dNIHR Biomedical Research Centre, University College London Hospitals, London, UK

Correspondence to David S. Hui, Department of Medicine & Therapeutics, Stanley Ho Center for Emerging Infectious Diseases, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, New Territories, Hong Kong. Tel: +852 2632 3128; fax: +852 2648 9957; e-mail:

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins